BioNexus Gene Lab Corp Income Statement
BGLC|7 years of annual SEC 10-K data (FY2019-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 7 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Revenue
$7M
FY2025
Gross Profit
$1M
14.6% gross margin
Operating Income
-$3M
FY2025
Net Income
-$3M
FY2025
BioNexus Gene Lab Corp reported $7M in revenue and $3M in net loss for FY2025. Revenue has grown at a 97.0% compound annual rate over the past 6 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 5.27 (safe zone, above 2.9 threshold)
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
- Negative return on equity: -34.6% ROE
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $7.4M | $9.5M | $9.8M | $10.9M | $13.4M | $11.4M | $127.0K |
| Cost of Revenue | $6.3M | $8.2M | $8.4M | $9.7M | $11.1M | $9.7M | $71.1K |
| Gross Profit | $1.1M | $1.3M | $1.3M | $1.3M | $2.3M | $1.7M | $55.9K |
| SG&A Expense | $1.5M | $1.8M | $2.4M | $1.7M | $1.3M | $1.3M | $356.6K |
| R&D Expense | $50.7K | $47.5K | $55.0K | - | - | - | - |
| Operating Income | -$3.0M | -$1.6M | -$2.6M | -$291.2K | $1.1M | $1.3M | -$275.7K |
| Interest Expense | - | - | $13.9K | $12.5K | - | - | - |
| Income Tax | $0 | -$3.5K | -$21.5K | -$52.3K | -$291.3K | - | $24.8K |
| Net Income | -$3.0M | -$1.6M | -$2.6M | -$356.0K | $751.6K | $1.1M | -$246.5K |
| EPS (Diluted) | - | -$0.17 | - | - | - | $0.00 | $0.00 |
| Shares Outstanding | 1.8M | 17.7M | 14.5M | 171.2M | 171.2M | 102.7M | 74.6M |
| Gross Margin | 14.6% | 13.6% | 13.6% | 11.5% | 17.0% | 15.1% | 44.0% |
| Operating Margin | -39.9% | -16.6% | -26.5% | -2.7% | 7.9% | 11.2% | -217.2% |
| Profit Margin | -40.2% | -16.8% | -26.9% | -3.3% | 5.6% | 9.6% | -194.1% |